Flow Cytometry in Multi-center and Longitudinal Studies

In the era of consortium-based studies, “omics,” and data sharing, flow cytometry needs to match other technological platforms in terms of standard operating procedures, reduced variability, and reproducibility. While tools such as gene-expression platforms have proven robustness and reproducibility, flow cytometry still relies heavily on scientists for the development of antibody panels as well as detailed experimental procedures. This is expected to remain for several decades, as the limit of markers to be assessed in a single staining does not allow attainment of the “omic” level of other technological platforms. This chapter presents a non-exhaustive series of multi-centric and longitudinal studies and their integration of flow cytometry measures. We also discuss recommendations made by key consortia to minimize variability in flow cytometry experiments. This chapter also aims to raise awareness of factors that may influence flow cytometry data obtained in large studies.